Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.
about
Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animalsThe Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including AtherosclerosisDPP4 in DiabetesMilk proteins, peptides, and oligosaccharides: effects against the 21st century disordersDifferential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort studyProtection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection.The dipeptidyl peptidase-4 inhibitor saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patientsThe nonglycemic actions of dipeptidyl peptidase-4 inhibitorsPleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular systemCardiovascular effects of incretin therapy in diabetes care.Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cellsCardiovascular impact of drugs used in the treatment of diabetesPreventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null miceDipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearmSGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.Sarcoid-like lung granulomas in a hemodialysis patient treated with a dipeptidyl peptidase-4 inhibitorDesign and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.Interpretation of cardiovascular outcome trials in type 2 diabetes needs a multiaxial approach.Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data.Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus.Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors.Saxagliptin Improves Glucose Tolerance but not Survival in a Murine Model of Dilated CardiomyopathyDipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese ratsDPP-4 Inhibitors as Therapeutic Modulators of Immune Cell Function and Associated Cardiovascular and Renal Insulin Resistance in Obesity and Diabetes.Lower dipeptidyl peptidase-4 following exercise training plus weight loss is related to increased insulin sensitivity in adults with metabolic syndrome.Associations of dipeptidyl peptidase-4 inhibitors with mortality in hospitalized heart failure patients with diabetes mellitus.Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes.Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition.A review of gliptins in 2011.Cardiovascular effects of the DPP-4 inhibitors.Examining the role of insulin in the regulation of cardiovascular health.Cardiovascular effects of gliptins.The emerging role of dipeptidyl peptidase-4 inhibitors in cardiovascular protection: current position and perspectives.Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach.The role of DPP4 activity in cardiovascular districts: in vivo and in vitro evidenceDirect cardiovascular effects of glucagon like peptide-1.Renal Effects of DPP-4 Inhibitors: A Focus on MicroalbuminuriaThe use of non-insulin anti-diabetic agents to improve glycemia without hypoglycemia in the hospital setting: focus on incretins.
P2860
Q26749176-003DF390-C3B7-400F-9ECA-4D1100CCBB53Q26795473-B0145D8A-47F2-4057-8386-40965A63F47CQ26797335-54138F9A-CA04-4956-B24E-FFC8CF801EE1Q27023113-FE092A36-C64D-49AA-81E5-4CDDBE3E0882Q28547367-97F99D08-35CC-498C-B0F4-060049405C50Q30390165-4C1DA5A2-7834-44CD-AF09-C7A83227F025Q33662677-BA658D2A-A077-454D-830F-62643F6F8814Q34029715-D84A450A-AF51-4E90-8457-A0D604B586FBQ34062829-D6E82CE5-F3D0-44B7-8B87-75E382353DDEQ34171759-0166FBDA-6CF1-4A28-A47F-D3907624686BQ34334364-07EDE7B8-C2AB-4A13-8690-E2C65C9999E8Q34383575-A24C21C6-95ED-4867-9015-E883296A7AC8Q34963221-7B15B540-0CF6-42FA-8DBB-BDB425AFE9F9Q35026385-F4753140-7989-46A5-9FC8-05EB51ADF0E5Q35181821-40514FAC-5A95-4ECC-827C-346531C6B49DQ35227626-96169F25-7935-48CD-9C12-9D175C79BE23Q35330816-63F59647-5443-477B-BC91-8383BFE261ABQ35777074-C93C5C13-08B7-4407-83CD-DDAC6883E160Q35932559-28A5A7BC-030B-449A-9A07-9472DBD8A135Q36376273-0E4C0DCF-2782-4A97-BE29-70E1E546B58BQ36715125-A49D7FCD-A44E-4AE9-94D0-4C61D262DA59Q36883337-CCFED39B-025C-40E1-B79A-5E40FDCCA7A3Q36939647-C56A004E-4BDB-481F-9E50-51A9030E4290Q36946065-A7BCBC69-8FE8-487C-8029-52ADB227B1B8Q37095161-3139298A-6694-45DB-B7DA-07F7D0418503Q37301797-3EEC8ED5-DA5B-4746-9BE2-495DE404D297Q37337371-59B39746-E6B3-475D-AD70-716A0CDACAF8Q37620904-C6B78E83-CE80-47DE-86D1-564C845E3A56Q37699068-14EEA5C8-061F-489D-BD13-97A304502202Q37965612-6F1369B3-CA4A-444A-936A-A0909C023C11Q37984287-0F4F3936-72EA-450B-9218-3B2C6441EEF2Q38069198-9E1FF53F-5563-48D5-A49F-A12DD0407D56Q38072259-77B346CF-34F2-48EF-87AE-75281510E978Q38104293-47E3CAC3-F4D5-4AB2-8F5D-208F1A19C6FFQ38113092-7494FFB1-0637-4243-9005-148BCD8D46CFQ38119146-48ACD150-749C-4989-8593-CCCC253555B1Q38121545-EA798743-17C0-4758-9AEE-19136F77CB42Q38132470-F78FA85C-D3B3-4561-B5F4-3BEAA7E84913Q38148750-7FAF06B6-2BD0-4F39-905A-53F8AF601F69Q38187004-88FF13C8-1643-4D4B-96E2-C4E265C2A544
P2860
Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.
@en
Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.
@nl
type
label
Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.
@en
Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.
@nl
prefLabel
Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.
@en
Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.
@nl
P1476
Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.
@en
P2093
Angelo Avogaro
Gian Paolo Fadini
P356
10.1016/J.VPH.2011.05.001
P577
2011-05-31T00:00:00Z